---
title: "Adrabetadex (Lembaz) in Infantile-onset Niemann-Pick disease type C: VTS-270-001"
description: "Formulary evidence on Adrabetadex (Lembaz, VTS-270) in Infantile-onset Niemann-Pick disease type C: VTS-270-001. Covers Objective, Location and study date, Study design, Eligibility criteria, Treatment, Study outcomes, and 3 further headings. 34 evidence topics quoted from 5 sources."
canonical: "https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/clinical-evidence/vts-270-001"
published: "2026-11-19T12:08:36-05:00"
modified: "2026-11-19T12:08:36-05:00"
---

# Adrabetadex (Lembaz) in Infantile-onset Niemann-Pick disease type C: VTS-270-001

<a id="heading-3.1.4"></a>

## 3.1.4 VTS-270-001

<a id="heading-3.1.4.1"></a>

### 3.1.4.1 Objective

<a id="topic-3.1.4.1-1"></a>

#### Registered objective: long-term safety and effectiveness

> “Information will be collected about long-term safety and effectiveness of adrabetadex shots in the spine every 2 weeks.”

Source: [ClinicalTrials.gov NCT03643562](https://clinicaltrials.gov/study/NCT03643562)

<a id="topic-3.1.4.1-2"></a>

#### Protocol primary and secondary objectives

| Objective | Protocol text |
| --- | --- |
| Primary objective | “To evaluate the longer-term safety and tolerability of adrabetadex administered IT via LP every 2 weeks” |
| Secondary objective | “To summarize additional longer-term safety and tolerability of adrabetadex administered IT via LP every 2 weeks” |

Source: [Mallinckrodt VTS-270-001 protocol (2021)](https://cdn.clinicaltrials.gov/large-docs/62/NCT03643562/Prot_SAP_001.pdf)

<a id="heading-3.1.4.2"></a>

### 3.1.4.2 Location and Study Date

<a id="topic-3.1.4.2-1"></a>

#### Registry study dates

| Field | Registry record |
| --- | --- |
| Study start (actual) | “2018-06-18” |
| Primary completion (actual) | “2021-11-02” |
| Study completion (actual) | “2021-11-02” |
| First posted | “2018-08-23” |
| Results first posted | “2024-01-17” |

Source: [ClinicalTrials.gov NCT03643562](https://clinicaltrials.gov/study/NCT03643562)

<a id="topic-3.1.4.2-2"></a>

#### Study sites in the United States

> “This study has 17 locations”

Source: [ClinicalTrials.gov NCT03643562](https://clinicaltrials.gov/study/NCT03643562)

| Facility | Location |
| --- | --- |
| “University of Arkansas System” | “Little Rock, Arkansas, United States, 72205” |
| “Loma Linda University Health System” | “Loma Linda, California, United States, 92354” |
| “Children's Hospital Los Angeles” | “Los Angeles, California, United States, 90027” |
| “Children's Hospital of Orange County” | “Orange, California, United States, 92868” |
| “Children's Hospital Colorado” | “Aurora, Colorado, United States, 80045” |
| “Children's National Hospital” | “Washington D.C., District of Columbia, United States, 20010” |
| “Rare Disease Research, LLC” | “Atlanta, Georgia, United States, 30318” |
| “Rush University Medical Center” | “Chicago, Illinois, United States, 60612” |
| “Gillette Children's Specialty Healthcare” | “Saint Paul, Minnesota, United States, 55101” |
| “Children's Specialty Center of Nevada” | “Las Vegas, Nevada, United States, 89109” |
| “NYU Langone Medical Center” | “New York, New York, United States, 10017” |
| “Cincinnati Children's Hospital Medical Center” | “Cincinnati, Ohio, United States, 45229” |
| “Oregon Health & Science University” | “Portland, Oregon, United States, 97239” |
| “The Children's Hospital at TriStar Centennial” | “Nashville, Tennessee, United States, 37203” |
| “Vanderbilt University Medical Center” | “Nashville, Tennessee, United States, 37232” |
| “Dell Children's Medical Center of Central Texas” | “Austin, Texas, United States, 78723” |
| “Carilion Medical Center, Carilion Clinic” | “Roanoke, Virginia, United States, 24014” |

Source: [ClinicalTrials.gov NCT03643562](https://clinicaltrials.gov/study/NCT03643562)

<a id="topic-3.1.4.2-3"></a>

#### Protocol dates and end of treatment in October 2021

| Field | Protocol text |
| --- | --- |
| Original protocol | “Date of Original Protocol: 01 December 2017” |
| Protocol amendment 3 | “Date of Protocol Amendment 3: 23 June 2021” |

Source: [Mallinckrodt VTS-270-001 protocol (2021)](https://cdn.clinicaltrials.gov/large-docs/62/NCT03643562/Prot_SAP_001.pdf)

> “Following a determination of a negative benefit/risk balance by the Sponsor, treatment will be allowed to continue up to 20 October 2021.”

Source: [Mallinckrodt VTS-270-001 protocol (2021)](https://cdn.clinicaltrials.gov/large-docs/62/NCT03643562/Prot_SAP_001.pdf)

<a id="heading-3.1.4.3"></a>

### 3.1.4.3 Study Design

<a id="topic-3.1.4.3-1"></a>

#### Open-label single-arm trial in treatment-naive and previously treated participants

> “Trial 3 (NCT03643562) was a non-randomized, open-label, single-arm trial that enrolled 27 patients (9 treatment-naïve, 18 previously treated through expanded access program) with neurological manifestations of NPC between 4 and 43 years of age.”

Source: [Lembaz prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/220996s000lbl.pdf)

<a id="topic-3.1.4.3-2"></a>

#### Registry design fields and conversion from expanded access

> “This study was amended from expanded access to a clinical trial.”

Source: [ClinicalTrials.gov NCT03643562](https://clinicaltrials.gov/study/NCT03643562)

| Field | Registry record |
| --- | --- |
| Official title | “Open-label Evaluation of Adrabetadex in Patients With Neurologic Manifestations of Niemann-Pick Type C Disease (NPC)” |
| Other study ID | “VTS-270-001” |
| Study type | “Interventional” |
| Phase | “Phase 3” |
| Allocation | “N/A” |
| Interventional model | “Single Group Assignment” |
| Interventional model description | “Continued treatment for children at least 4 years of age” |
| Masking | “None (Open Label)” |

Source: [ClinicalTrials.gov NCT03643562](https://clinicaltrials.gov/study/NCT03643562)

<a id="topic-3.1.4.3-3"></a>

#### Protocol design: prospective open-label safety study without a control group

> “This is a prospective, open-label study to evaluate the longer-term safety of adrabetadex in subjects with neurological symptoms of NPC type C disease.”
> “No control product will be used in the study.”
> “No data monitoring committee will be used in this study.”

Source: [Mallinckrodt VTS-270-001 protocol (2021)](https://cdn.clinicaltrials.gov/large-docs/62/NCT03643562/Prot_SAP_001.pdf)

<a id="topic-3.1.4.3-4"></a>

#### Protocol amendment 3: sponsor recommendation to discontinue treatment and benefit assessment for continuation

> “Effective 20 January 2021, Mallinckrodt is recommending that treatment with adrabetadex be discontinued as soon as possible with appropriate clinician oversight.”
> “In recognition of the complexity of patient care, Mallinckrodt will make adrabetadex available for up to 9 months to allow time for the physician and subject/family to develop a transition plan.”
> “For subjects continuing in this study after 21 June 2021, the investigator must assess whether the subject is benefiting from treatment with adrabetadex.”
> “Subjects must be discontinued from the study if the investigator does not consider them to be benefiting from treatment and/or they do not understand the risks associated with adrabetadex, including hearing loss.”

Source: [Mallinckrodt VTS-270-001 protocol (2021)](https://cdn.clinicaltrials.gov/large-docs/62/NCT03643562/Prot_SAP_001.pdf)

<a id="heading-3.1.4.4"></a>

### 3.1.4.4 Eligibility Criteria

<a id="topic-3.1.4.4-1"></a>

#### Registry inclusion criteria

> “Is male or female and at least 4 years of age at time of screening.”
> “Has a confirmed diagnosis of NPC and exhibits neurologic symptoms.”
> “Has the ability to undergo LP and IT drug administration.”
> “If taking miglustat (Zavesca®), must have been on a stable dose for the past 6 weeks and be willing to remain on a stable dose for the duration of participation in the study, or discontinue miglustat use at least 6 weeks before entry into the study (Day 1).”
> “If has a history of seizures, the condition is adequately controlled as per protocol requirements.”
> “Agrees to discontinue any investigational treatments (other than adrabetadex) for at least 1 month before first dose on Day 1.”

Source: [ClinicalTrials.gov NCT03643562](https://clinicaltrials.gov/study/NCT03643562)

<a id="topic-3.1.4.4-2"></a>

#### Registry exclusion criteria

> “Weighs less than 15 kg.”
> “Has a history of hypersensitivity reactions to any product containing 2-hydroxypropyl-β-cyclodextrin (HP-β-CD) or has a history of hypersensitivity reactions or allergy to anesthesia/sedation.”
> “Has received treatment with any investigational product (other than adrabetadex) within 1 month prior to Day 1 of treatment.”
> “Has systemic infection or uncontrolled psychosis.”
> “Has known history of a bleeding disorder.”
> “Has used anticoagulants within 2 months of entry into the study.”

Source: [ClinicalTrials.gov NCT03643562](https://clinicaltrials.gov/study/NCT03643562)

<a id="topic-3.1.4.4-3"></a>

#### Protocol criteria for participants already receiving adrabetadex and for hydrocephalus

> “If not currently receiving adrabetadex, agrees to discontinue any other investigational treatments for at least 1 month prior to first dose of adrabetadex (Day 1); subjects who are currently receiving intrathecal adrabetadex are eligible to participate.”
> “Has evidence of obstructive hydrocephalus or normal pressure hydrocephalus.”

Source: [Mallinckrodt VTS-270-001 protocol (2021)](https://cdn.clinicaltrials.gov/large-docs/62/NCT03643562/Prot_SAP_001.pdf)

<a id="heading-3.1.4.5"></a>

### 3.1.4.5 Treatment

<a id="topic-3.1.4.5-1"></a>

#### Starting dosage by prior treatment status

> “Treatment-naïve patients started at LEMBAZ 400 mg intrathecally every two weeks, while patients already receiving LEMBAZ continued at their current stable dosage intrathecally every two weeks.”
> “The Trial 3 duration was open-ended; mean (SD) duration of LEMBAZ treatment was 75 (36) weeks.”

Source: [Lembaz prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/220996s000lbl.pdf)

<a id="topic-3.1.4.5-2"></a>

#### Registry arm description and treatment duration

> “Participants will receive prescribed adrabetadex by intra-thecal (IT) injection every 2 weeks.”
> “Participants who were already taking adrabetadex will receive their stable dose. Participants who have not ever taken it will start by receiving 400 mg.”
> “Participants will receive treatment every 2 weeks until their doctor finds it does not help them anymore, they withdraw, or the study is stopped for any reason.”

Source: [ClinicalTrials.gov NCT03643562](https://clinicaltrials.gov/study/NCT03643562)

<a id="topic-3.1.4.5-3"></a>

#### Protocol dose preparation and lumbar puncture administration

> “The total infusion volume should be 10 mL; to achieve a final total volume of 10 mL, 0.9% sterile sodium chloride for injection, USP should be added to the adrabetadex solution.”
> “Adrabetadex will be administered as an IT slow bolus (1 to 2 minutes, depending on the volume administered) LP injection (maximum rate of administration = 4.5 mL/minute).”
> “Prior to the adrabetadex injection, a volume of cerebrospinal fluid approximately equal to the infusion volume (approximately 10 mL) will be removed.”
> “Patients will be required, if possible, to lie flat with feet elevated for 30 to 45 minutes following dosing.”
> “For the 3 days following each procedure, subjects should avoid acoustic overstimulation and minimize exposure to loud noises, eg, headphones for music or video games.”

Source: [Mallinckrodt VTS-270-001 protocol (2021)](https://cdn.clinicaltrials.gov/large-docs/62/NCT03643562/Prot_SAP_001.pdf)

<a id="topic-3.1.4.5-4"></a>

#### Protocol dose adjustment rules and dose increases stopped in April 2021

> “Patients who, in the opinion of the clinician, experience a drug-related adverse event (AE) after any IT treatment that is considered clinically relevant and impactful to the subject’s function may have their dose reduced back to the previously tolerated dose.”
> “The lowest dose is 400 mg; subjects unable to tolerate 400 mg will be discontinued from the study.”
> “Effective as of the date of Amendment 2 (21 April 2021), subjects will remain at their current dose or their dose may be decreased for tolerability reasons.”
> “There are no adjustments of dosing regimen for weight or subject age.”

Source: [Mallinckrodt VTS-270-001 protocol (2021)](https://cdn.clinicaltrials.gov/large-docs/62/NCT03643562/Prot_SAP_001.pdf)

<a id="topic-3.1.4.5-5"></a>

#### Protocol concomitant medication restrictions

> “Use of anticoagulants is prohibited during the study.”
> “The use of other investigational medications and treatments is also prohibited.”

Source: [Mallinckrodt VTS-270-001 protocol (2021)](https://cdn.clinicaltrials.gov/large-docs/62/NCT03643562/Prot_SAP_001.pdf)

<a id="heading-3.1.4.6"></a>

### 3.1.4.6 Study Outcomes

<a id="heading-3.1.4.6.1"></a>

#### 3.1.4.6.1 Rationale for Using Treatment-emergent Adverse Events as the Primary Endpoint

<a id="topic-3.1.4.6.1-1"></a>

##### Registered primary outcome measure

| Field | Registry record |
| --- | --- |
| Outcome measure | “Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)” |
| Time frame | “Baseline up to Week 134” |

Source: [ClinicalTrials.gov NCT03643562](https://clinicaltrials.gov/study/NCT03643562)

<a id="topic-3.1.4.6.1-2"></a>

##### Registry definition of treatment-emergent and serious adverse events

> “A TEAE was defined as an AE with onset on or after the start of adrabetadex treatment.”
> “Serious adverse events (SAEs) were defined as death, a life-threatening AE, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability or incapacity, a congenital anomaly or birth defect, or an important medical event that jeopardized participant and required medical intervention to prevent 1 of the outcomes listed in this definition.”

Source: [ClinicalTrials.gov NCT03643562 API record](https://clinicaltrials.gov/api/v2/studies/NCT03643562)

<a id="topic-3.1.4.6.1-3"></a>

##### Protocol primary and secondary safety endpoints

| Endpoint | Protocol text |
| --- | --- |
| Primary endpoint | “Summary of TEAEs, SAEs, discontinuation due to TEAEs, and deaths” |
| Secondary endpoint | “Change in audiologic testing.” |
| Secondary endpoint | “Laboratory changes from baseline (hematology, chemistry, coagulation, urinalysis.)” |
| Secondary endpoint | “Vital sign measurements.” |

Source: [Mallinckrodt VTS-270-001 protocol (2021)](https://cdn.clinicaltrials.gov/large-docs/62/NCT03643562/Prot_SAP_001.pdf)

<a id="topic-3.1.4.6.1-4"></a>

##### Protocol definition of a clinically significant hearing change

| Criterion | Protocol text |
| --- | --- |
| Single frequency | “≥20 dB increase at any one test frequency relative to baseline measure.” |
| Adjacent frequencies | “≥10 dB increase at any two adjacent test frequencies relative to baseline measure.” |
| Loss of response | “Loss of response at three consecutive test frequencies where responses were previously obtained (specifically the highest frequencies tested) on baseline measure.” |

Source: [Mallinckrodt VTS-270-001 protocol (2021)](https://cdn.clinicaltrials.gov/large-docs/62/NCT03643562/Prot_SAP_001.pdf)

> “As of 20 January 2021, ABRs will not be collected, as the potential risks with the procedure outweigh the potential benefit of the data.”

Source: [Mallinckrodt VTS-270-001 protocol (2021)](https://cdn.clinicaltrials.gov/large-docs/62/NCT03643562/Prot_SAP_001.pdf)

<a id="heading-3.1.4.7"></a>

### 3.1.4.7 Statistical Analysis Description

<a id="heading-3.1.4.7.1"></a>

#### 3.1.4.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.4.7.1-1"></a>

##### Planned enrollment and enrollment closure in January 2021

> “The study is anticipated to enroll approximately 60 subjects from 30 sites in the US.”
> “Effective 20 January 2021, no new subjects can be enrolled in the study.”

Source: [Mallinckrodt VTS-270-001 protocol (2021)](https://cdn.clinicaltrials.gov/large-docs/62/NCT03643562/Prot_SAP_001.pdf)

<a id="topic-3.1.4.7.1-2"></a>

##### Actual enrollment and participants analyzed by group

| Field | Treatment naive | Previously treated | Total |
| --- | --- | --- | --- |
| Overall number of baseline participants | “9” | “18” | “27” |

Source: [ClinicalTrials.gov NCT03643562 results](https://clinicaltrials.gov/study/NCT03643562?tab=results)

<a id="heading-3.1.4.7.2"></a>

#### 3.1.4.7.2 Description of Analysis Sets

<a id="topic-3.1.4.7.2-1"></a>

##### Registry analysis population for baseline, outcome, and adverse event data

| Field | Registry record |
| --- | --- |
| Baseline, outcome, and adverse event analysis population | “All enrolled participants” |

Source: [ClinicalTrials.gov NCT03643562 results](https://clinicaltrials.gov/study/NCT03643562?tab=results)

<a id="topic-3.1.4.7.2-2"></a>

##### Protocol statistical methods: descriptive statistics without imputation

> “Study data will be summarized using descriptive statistics.”
> “No hypothesis testing will be conducted.”
> “All analyses will be based on available data.”
> “Missing data will not be imputed.”
> “Data generated in this study may be pooled with others in the adrabetadex clinical program or from historical cohort for comparison.”
> “Treatment-emergent AEs (TEAEs) are defined as those AEs that are not present at Day 1 of study or represent the exacerbation of a pre-existing condition during the treatment period.”

Source: [Mallinckrodt VTS-270-001 protocol (2021)](https://cdn.clinicaltrials.gov/large-docs/62/NCT03643562/Prot_SAP_001.pdf)

<a id="heading-3.1.4.8"></a>

### 3.1.4.8 Results

<a id="heading-3.1.4.8.1"></a>

#### 3.1.4.8.1 Participant Disposition

<a id="topic-3.1.4.8.1-1"></a>

##### Registry participant flow and reasons for not completing

| Milestone or reason | Treatment naive | Previously treated |
| --- | --- | --- |
| Started | “9” | “18” |
| Received at least 1 dose of study drug | “9” | “18” |
| Completed | “1” | “2” |
| Not completed | “8” | “16” |
| Adverse event | “1” | “0” |
| Lack of efficacy | “0” | “1” |
| Other than specified | “3” | “2” |
| Physician decision | “0” | “1” |
| Study terminated by sponsor | “2” | “10” |
| Withdrawal by subject | “2” | “2” |

Source: [ClinicalTrials.gov NCT03643562 results](https://clinicaltrials.gov/study/NCT03643562?tab=results)

<a id="heading-3.1.4.8.2"></a>

#### 3.1.4.8.2 Baseline Characteristics

<a id="topic-3.1.4.8.2-1"></a>

##### Registry baseline demographics

| Characteristic | Treatment naive (n=9) | Previously treated (n=18) | Total (n=27) |
| --- | --- | --- | --- |
| Age, mean (SD), years | “12.33(8.718)” | “17.94(13.705)” | “16.07(12.388)” |
| Female, participants | “4” | “7” | “11” |
| Male, participants | “5” | “11” | “16” |
| Hispanic or Latino, participants | “1” | “0” | “1” |
| White, participants | “7” | “17” | “24” |
| Black or African American, participants | “0” | “1” | “1” |
| Race unknown or not reported, participants | “2” | “0” | “2” |

Source: [ClinicalTrials.gov NCT03643562 results](https://clinicaltrials.gov/study/NCT03643562?tab=results)

<a id="heading-3.1.4.8.3"></a>

#### 3.1.4.8.3 Efficacy Results

<a id="topic-3.1.4.8.3-1"></a>

##### Efficacy and patient-reported outcome assessments not collected under the amended protocol

> “Efficacy assessments (NPC-severity scale [NPC-SS], Clinician Clinical Global Impression of Change [CGIC]) and self-reported outcomes (EuroQol five-dimensional three-level version [EQ-5D-3L]) will not be collected or analyzed.”

Source: [Mallinckrodt VTS-270-001 protocol (2021)](https://cdn.clinicaltrials.gov/large-docs/62/NCT03643562/Prot_SAP_001.pdf)

<a id="heading-3.1.4.8.4"></a>

#### 3.1.4.8.4 Health-related Quality of Life and Patient-reported Outcomes

No evidence found.

<a id="heading-3.1.4.8.5"></a>

#### 3.1.4.8.5 Safety Results

<a id="topic-3.1.4.8.5-1"></a>

##### Primary outcome: participants with treatment-emergent and serious adverse events

| Outcome | Treatment naive (n=9) | Previously treated (n=18) |
| --- | --- | --- |
| All TEAEs, participants | “9” | “17” |
| SAEs, participants | “5” | “9” |

Source: [ClinicalTrials.gov NCT03643562 results](https://clinicaltrials.gov/study/NCT03643562?tab=results)

<a id="topic-3.1.4.8.5-2"></a>

##### All-cause mortality and serious adverse events by preferred term

| Event | Treatment naive | Previously treated |
| --- | --- | --- |
| All-cause mortality | “0/9 (0.00%)” | “0/18 (0.00%)” |
| Any serious adverse event | “5/9 (55.56%)” | “9/18 (50.00%)” |
| Deafness | “1/9 (11.11%)” | “0/18 (0.00%)” |
| Pneumonia | “1/9 (11.11%)” | “2/18 (11.11%)” |
| Pneumonia aspiration | “0/9 (0.00%)” | “2/18 (11.11%)” |
| Acute respiratory failure | “2/9 (22.22%)” | “0/18 (0.00%)” |
| Respiratory distress | “0/9 (0.00%)” | “1/18 (5.56%)” |
| Hypoxia | “0/9 (0.00%)” | “1/18 (5.56%)” |
| Meningitis | “1/9 (11.11%)” | “0/18 (0.00%)” |
| Staphylococcal bacteraemia | “1/9 (11.11%)” | “0/18 (0.00%)” |
| Seizure | “1/9 (11.11%)” | “3/18 (16.67%)” |
| Ataxia | “1/9 (11.11%)” | “0/18 (0.00%)” |
| Sedation | “1/9 (11.11%)” | “0/18 (0.00%)” |
| Vomiting | “1/9 (11.11%)” | “0/18 (0.00%)” |
| Post procedural haemorrhage | “0/9 (0.00%)” | “1/18 (5.56%)” |
| Femur fracture | “1/9 (11.11%)” | “0/18 (0.00%)” |
| Acute kidney injury | “0/9 (0.00%)” | “1/18 (5.56%)” |

Source: [ClinicalTrials.gov NCT03643562 results](https://clinicaltrials.gov/study/NCT03643562?tab=results)

<a id="topic-3.1.4.8.5-3"></a>

##### Selected other (non-serious) adverse events reported at a 5% frequency threshold

| Event | Treatment naive | Previously treated |
| --- | --- | --- |
| Any other adverse event | “9/9 (100.00%)” | “17/18 (94.44%)” |
| Hypoacusis | “2/9 (22.22%)” | “4/18 (22.22%)” |
| Deafness | “0/9 (0.00%)” | “2/18 (11.11%)” |
| Deafness neurosensory | “0/9 (0.00%)” | “2/18 (11.11%)” |
| Fatigue | “6/9 (66.67%)” | “7/18 (38.89%)” |
| Ataxia | “5/9 (55.56%)” | “6/18 (33.33%)” |
| Vomiting | “4/9 (44.44%)” | “4/18 (22.22%)” |
| Headache | “3/9 (33.33%)” | “2/18 (11.11%)” |
| Back pain | “3/9 (33.33%)” | “0/18 (0.00%)” |
| Pyrexia | “3/9 (33.33%)” | “3/18 (16.67%)” |
| Somnolence | “0/9 (0.00%)” | “4/18 (22.22%)” |
| Seizure | “2/9 (22.22%)” | “1/18 (5.56%)” |
| Upper respiratory tract infection | “3/9 (33.33%)” | “8/18 (44.44%)” |

Source: [ClinicalTrials.gov NCT03643562 results](https://clinicaltrials.gov/study/NCT03643562?tab=results)

<a id="heading-3.1.4.9"></a>

### 3.1.4.9 Study Limitations

<a id="topic-3.1.4.9-1"></a>

#### Summary: design limitations of VTS-270-001

- Control and blinding: VTS-270-001 was a non-randomized, open-label, single-arm trial with masking recorded as none; the protocol used no control product and no data monitoring committee.
- Sample size and population: the protocol anticipated approximately 60 subjects from 30 sites, and no new subjects could enroll after 20 January 2021. The trial enrolled 27 participants (9 treatment-naïve and 18 previously treated through the expanded access program) aged 4 to 43 years. Treatment-naïve participants started at 400 mg, previously treated participants continued at their current stable dosage, and dose increases stopped as of Amendment 2 (21 April 2021).
- Missing efficacy collection: under the amended protocol, efficacy assessments (NPC-SS and clinician CGIC) and the EQ-5D-3L were not collected or analyzed, and auditory brainstem responses were not collected as of 20 January 2021.
- Analysis: data were summarized with descriptive statistics, with no hypothesis testing and no imputation of missing data.
- Early termination: the trial was terminated early when the sponsor determined that the benefit-risk profile of adrabetadex was not favorable, and treatment was allowed to continue up to 20 October 2021. Of 27 participants, 1 treatment-naive and 2 previously treated participants completed; study termination by the sponsor accounted for 2 and 10 participants. After 21 June 2021, continuation required the investigator to assess that the subject was benefiting from treatment.
- Sponsor statements: the protocol states that a comprehensive evaluation of all available clinical data “shows no clear evidence of benefit of adrabetadex in the treatment of neurologic symptoms of NPC” and that “the benefit/risk balance is negative.”

Source: [Lembaz prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/220996s000lbl.pdf); [ClinicalTrials.gov NCT03643562](https://clinicaltrials.gov/study/NCT03643562); [ClinicalTrials.gov NCT03643562 results](https://clinicaltrials.gov/study/NCT03643562?tab=results); [Mallinckrodt VTS-270-001 protocol (2021)](https://cdn.clinicaltrials.gov/large-docs/62/NCT03643562/Prot_SAP_001.pdf)

<a id="topic-3.1.4.9-2"></a>

#### Registry limitations and caveats: early termination

> “This study was terminated early when the Sponsor had determined that the benefit-risk profile of adrabetadex was not favorable and the clinical development program for adrabetadex was discontinued.”

Source: [ClinicalTrials.gov NCT03643562 results](https://clinicaltrials.gov/study/NCT03643562?tab=results)

<a id="topic-3.1.4.9-3"></a>

#### Prior sponsor's benefit-risk conclusion stated in the protocol, June 2021

> “Although there are case reports from a few expert treating physicians indicating a potential benefit of adrabetadex in NPC patients treated over a period of time, a comprehensive evaluation of all available clinical data shows no clear evidence of benefit of adrabetadex in the treatment of neurologic symptoms of NPC.”
> “In view of established risks of treatment with adrabetadex, Mallinckrodt concludes that the benefit/risk balance is negative.”

Source: [Mallinckrodt VTS-270-001 protocol (2021)](https://cdn.clinicaltrials.gov/large-docs/62/NCT03643562/Prot_SAP_001.pdf)

## Related pages
- [Adrabetadex (Lembaz): Infantile-onset Niemann-Pick disease type C](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c) · [Markdown](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c.md)
- [Adrabetadex (Lembaz) in Infantile-onset Niemann-Pick disease type C: Terms and abbreviations](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/terms-and-abbreviations.md)
- [Adrabetadex (Lembaz): Infantile-onset Niemann-Pick disease type C](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/executive-summary) · [Markdown](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/executive-summary.md)
- [Adrabetadex (Lembaz) in Infantile-onset Niemann-Pick disease type C: Product information and disease description](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/product-information-and-disease-description.md)
- [Adrabetadex (Lembaz) in Infantile-onset Niemann-Pick disease type C: Clinical evidence](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/clinical-evidence.md)
- [Adrabetadex (Lembaz) in Infantile-onset Niemann-Pick disease type C: Economic information and modeling report](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/economics) · [Markdown](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/economics.md)
- [Adrabetadex (Lembaz) in Infantile-onset Niemann-Pick disease type C: References](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/references) · [Markdown](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/references.md)
